Official Indications for EMVITAL
EMVITAL is intended to emit energy in the visible and infrared spectrum to provide topical heating for the purpose of elevating tissue temperature for the temporary relief of muscle and joint pain and stiffness, minor arthritis pain, or muscle spasm; the temporary increase in local blood circulation; and/or the temporary relaxation of muscle.
Primary Clinical Trial
- ClinicalTrials.gov Identifier
- NCT07661121
- Title
- EMVITAL + EMFACE Combination Therapy for Temporomandibular Joint (TMJ) Pain Relief
- Sponsor
- BTL Industries Ltd.
- Status (as of last update June 22, 2026)
- Active, not recruiting
- Published results
- No published numerical results available as of August 2026.
FDA Status
EMVITAL is marketed by BTL Industries as an FDA-cleared Class II medical device for the indications listed above. A standalone 510(k) summary publicly indexed under the exact trade name “EMVITAL” is not readily available in open FDA database searches as of August 2026. The device operates under BTL’s cleared infrared/laser heating technology platform (associated with models such as BTL-043).